Clinical Trial

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.
Protocol Amendment History 2 changes
notable Enrollment increased: 60 -> 66 participants 2026-07-31
critical Recruitment opened 2026-04-28
Trial Details
NCT Number NCT07533019
Lead Sponsor Eli Lilly and Company
Conditions Vitiligo, Non-Segmental Vitiligo (NSV)
Enrollment 66 participants
Start Date 2026-04-14
Primary Completion 2027-05 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06